# Explorative Clinical Investigation to Investigate the Ability of PreciseInhale to Direct Regional Lung Targeting and Reduce the Degree of Throat Deposition and Subsequent Gastrointestinal Absorption in Healthy Volunteers After Inhalation of Test Drug Substances Via the PreciseInhale System

> **NCT04946630** · NA · COMPLETED · sponsor: **Inhalation Sciences Sweden AB** · enrollment: 12 (actual)

## Conditions studied

- Nebulizers and Vaporizers

## Interventions

- **DEVICE:** PreciseInhale
- **OTHER:** Seretide Evohaler forte

## Key facts

- **NCT ID:** NCT04946630
- **Lead sponsor:** Inhalation Sciences Sweden AB
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-07
- **Primary completion:** 2021-07-22
- **Final completion:** 2021-07-26
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-04-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04946630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04946630, "Explorative Clinical Investigation to Investigate the Ability of PreciseInhale to Direct Regional Lung Targeting and Reduce the Degree of Throat Deposition and Subsequent Gastrointestinal Absorption in Healthy Volunteers After Inhalation of Test Drug Substances Via the PreciseInhale System". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT04946630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*